GlassScriptPhysician profile
Colleen Anne Mitchell
NPI 1235119546
$8,524.77
in general payments reported to CMS, 2019-2025
24 companies · $2,769 in 2025
The $2,769 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,171 · 2023: $1,706 · 2024: $2,878 · 2025: $2,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,896 · Education: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,895.66 |
| Education | $457.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,704.28 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,673.99 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $1,169.07 | 2022-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $867.94 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $766.75 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $443.80 | 2022-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $365.25 | 2022-2025 | Adbry, Anzupgo, Spevigo |
| Dermavant Sciences, INC. | $363.00 | 2022-2024 | Vtama |
| Ucb, INC. | $307.11 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $296.72 | 2022-2025 | |
| Genzyme Corporation | $109.96 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $78.75 | 2022-2025 | |
| Galderma Laboratories, L.P. | $63.37 | 2024-2025 | Nemluvio |
| Fresenius Kabi USA, LLC | $57.83 | 2023 | Idacio |
| Arcutis Biotherapeutics, INC. | $37.31 | 2024-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $37.05 | 2022 | |
| Botanix Sb INC | $36.97 | 2025 | Sofdra |
| Incyte Corporation | $32.21 | 2023-2024 | Opzelura |
| Krystal Biotech INC | $24.60 | 2023 | Vyjuvek |
| Mallinckrodt Hospital Products INC. | $23.00 | 2025 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.01 | 2025 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.99 | 2024 | Cyltezo |
| Sun Pharmaceutical Industries INC. | $16.36 | 2022 | |
| Organon LLC | $12.45 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.